Irinotecan (drug)

DRUG6 trials

Conditions

BRAF V600 Colorectal CancerCancer of EsophagusCancer of the EsophagusChildhood Brain TumorChildhood CancerChildhood Solid TumorEsophageal CancerEsophageal Neoplasm

Phase 1

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

RecruitingNCT05652686

Phanes TherapeuticsExtrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Large Cell Neuroendocrine Cancer (LCNEC) +3

Start: 2023-09-05End: 2028-08-01Target: 203Updated: 2026-07-15

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

RecruitingNCT06208657

Australian & New Zealand Children's Haematology/Oncology GroupChildhood Brain Tumor, Childhood Cancer, Childhood Solid Tumor +2

Start: 2024-07-10End: 2035-12-01Target: 90Updated: 2026-01-28

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

RecruitingNCT07334301

University of BirminghamRelapsed Neuroblastoma

Start: 2024-11-11End: 2030-12-31Target: 160Updated: 2026-01-12

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Not yet recruitingNCT07364422

Onconic Therapeutics Inc.Gastric Cancer (GC)

Start: 2026-02-27End: 2029-02-28Target: 49Updated: 2026-01-23

Phase 2

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

CompletedNCT00318903

University of Alabama at BirminghamCancer of Esophagus, Cancer of the Esophagus, Esophageal Cancer +2

Start: 2002-01-31End: 2006-04-30Updated: 2023-05-25

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

RecruitingNCT07150247

Sun Yat-sen UniversityBRAF V600 Colorectal Cancer

Start: 2025-06-01End: 2028-06-30Target: 20Updated: 2025-09-26

Related Papers

A multicenter, open-label, single-arm, dose-finding and -expansion phase 1b/2 study to evaluate the safety and tolerability of nesuparib (JPI-547) in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer.

Journal of Clinical Oncology2026-05-28

An open-label, multicenter, phase 1/2 study of peluntamig (PT217), an anti-DLL3/anti-CD47 bispecific antibody, in patients with DLL3-expressing cancers such as SCLC, LCNEC and EP-NEC (SKYBRIDGE study).

Journal of Clinical Oncology2025-05-281 citations

Abstract A044: Immune profiling tools for adult and pediatric cancer: From whole genome and transcriptome sequencing to immunotherapy clinical trial design

Cancer Research2025-03-11

Abstract B015: Transcriptome-based assessment of immune infiltration for molecular selection of pediatric patients with solid tumors for combination immune checkpoint inhibitor therapy

Cancer Research2024-09-05

Abstract B066: Bridging patient reported outcomes and CTCAE to improve supportive care and trial design: The PROptimise initiative